Deferiprone Market, By Formulation (Tablet, Oral Solution and Capsules), By Indication (Transfusional Iron Overload and Ntdt Caused Iron Overload), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa)- Trends, Analysis and Forecast till 2034

Deferiprone Market accounted for US$ 39.5 million in 2024 and is estimated to be US$ 130.2 million by 2034 and is anticipated to register a CAGR of 14%.

[PDF] In adults and children 3 years of age and older with thalassemia (an inherited disorder that results in a reduced number of red blood cells) and sickle cell anemia, deferiprone is used to eliminate excess iron from the body.

The market for Deferiprone is anticipated to grow as the incidence of the deadly thalassemia condition rises. Thalassemia affects roughly 4.4 out of every 10,000 live births. In the general population, looking trait wise Approximately 1.7 percent of people on earth have the alpha or beta thalassemia trait, despite the fact that 5% of people worldwide have a globin variation, improving the healthcare sector's understanding of this statistics could boost the demand for Deferiprone Market

Increasing Healthcare Spending

Increase in healthcare spending by both private firms and government can boost the market for deferiprone. Increasing number of investments by private business in new research and development can expand portfolio and may result in Deferiprone market growth in future. Startups with unique technology seeking investment by larger firm to establish their position can intensify competition and can result in growth of Deferiprone Market.

Cost effectiveness of Deferiprone

For treating chronic iron overload in -thalassemia patients, deferiprone revealed to be the most economical option. Therefore, the use of DFP in these patients might lead to significant cost savings, which had led to high clinical utilization as well as a rise in customer base and potential market expansion for Deferiprone.

Restrains:

Unfavorable effects including an increase in liver enzyme levels may necessitate blood tests by your doctor to evaluate your liver function prior to beginning Deferiprone treatment. This is also required for the month-to-month follow-up. The doctor may stop administering Deferiprone if the patient's liver enzyme levels are elevated.

Deferiprone Market is segmented based on Formulation, Indication and Region.

Formulation Insight

On the basis Formulation, Deferiprone Market is segmented Tablet, Oral Solution and Capsules. Tablet is expected to dominate the target market growth due to their cost effectiveness and convenience for use.

Indication Insights

On the basis of Indication, Deferiprone Market is segmented into Transfusional Iron Overload and Ntdt Caused Iron Overload. Transfusional Iron Overload are expected to dominate the target market growth as they are directly associated with number of blood transfusions.

Regional Insights:

On the basis of region, the Deferiprone Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is estimated to witness a significantly high revenue share over the forecast period, because of availability of good healthcare facility.

Report Scope:

Attribute	Details
Base year for estimation	2023
Forecast period	2024 – 2034
Market representation	Revenue in USD Billion & CAGR from 2024 to 2034
Market Segmentation	By Formulation – Tablet, Oral Solution, Capsules By Indication - Transfusional Iron Overload and Ntdt Caused Iron Overload
Regional scope	North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2022 to 2032. For the purpose of this study, has segmented the Deferiprone Market report based on Formulation, Indication and Region:

Deferiprone Market, By Formulations:

• Tablet
• Oral Solution
• Capsules

Deferiprone Market, By Indication:

• Transfusional Iron Overload
• Ntdt Caused Iron Overload

Deferiprone Market, By Region:

• • • North America
      • • U.S.
        • Canada
    • Europe
      • • Germany
        • UK
        • France
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • • China
        • India
        • Japan
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • • GCC
        • Israel
        • South Africa
        • Rest of Middle East & Africa

Recent Development:

• In May 2023, Deferiprone, a treatment for Parkinson's disease developed by “Chiesi Farmaceutici”, is now in Phase II of clinical trials and has a high likelihood of approval. The phase transition success rate (PTSR) indication threshold for moving into Phase III for Parkinson's disease medicines in Phase II is 41%, according to GlobalData.
• In May 2021, “Chiesi Global Rare Diseases” reports that FERRIPROX (deferiprone) has been approved by the FDA to treat transfusional iron overload brought on by sickle cell disease. With this FDA approval, FERRIPROX is now approved for use in patients with SCD, other anemias, and thalassemia regardless of prior iron chelation exposure.
• In September 2020, Deferiprone is an authorized iron chelator for the treatment of patients with thalassemia-related transfusional iron excess when other chelation therapies are ineffective. “Taro” has just introduced a new specialized generic version of the medication in the United States, available in 500mg tablet form. The equivalent of Ferriprox is called Deferiprone. With the introduction of this product, Taro may now provide specialty goods.

The key players operating the Deferiprone Market includes Cipla Limited, Apotex Inc., Swedish Orphan Biovitrum AB (publ), Genepharm S.A., Lipomed AG, Ambrosia Remedies (P) Ltd., Stryker, Axogen, Integra, Polyganics, and Focus Pharmaceuticals Limited.

• Cipla Limited *
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

• Apotex Inc.
• Swedish Orphan Biovitrum AB (publ),
• Genepharm S.A.,
• Lipomed AG,
•  Ambrosia Remedies (P) Ltd.,
• Stryker, Axogen,
• Integra,
• Polyganics,
•  Focus Pharmaceuticals Limited.

“*” marked represents similar segmentation in other categories in the respective section